摘要
摘要
Two large randomized, placebo-controlled phase 3 trials, CORALreef Lipids1 and CORALreef heFH,2 demonstrated that once-daily oral enlicitide lowered LDL cholesterol by approximately 56%-60% on top of background lipid-lowering therapy. Reductions were sustained through 24-52 weeks and accompanied by improvements in other lipid parameters. Safety outcomes were comparable to placebo, with efficacy similar to monoclonal antibody PCSK9 inhibitors.
KM 提取结果
0 个 Figure · 0 个 KM 面板